PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 16, 2017

Primary Completion Date

May 6, 2020

Study Completion Date

May 6, 2020

Conditions
Peritoneal CarcinomatosisOvarian Cancer Stage IIIBOvarian Cancer Stage IIICOvarian Cancer Stage IVBreast Cancer Stage IIIBBreast Cancer Stage IIIcBreast Cancer Stage IVStomach Cancer Stage IIIStomach Cancer Stage IV With MetastasesPancreas Cancer, Stage IIIPancreas Cancer, Stage IV
Interventions
DRUG

PIPAC with Abraxane

Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will escalate ranging from 35 to 140 mg/m². PIPAC will be performed every 4 weeks for 3 cycles.

Trial Locations (1)

9000

UZ Ghent, Ghent

All Listed Sponsors
collaborator

Kom Op Tegen Kanker

OTHER

collaborator

University Ghent

OTHER

collaborator

Hopital Lariboisière

OTHER

collaborator

University Women's Hospital Tübingen

OTHER

collaborator

Candiolo Cancer Institute - IRCCS

OTHER

collaborator

Centre Hospitalier Universitaire Vaudois

OTHER

lead

University Hospital, Ghent

OTHER

NCT03304210 - PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer | Biotech Hunter | Biotech Hunter